CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Biopharma News Pfizer announces US availability of biosimilar Inflectra
News
21 Oct 2016

Pfizer announces US availability of biosimilar Inflectra

Inflectra will be the first biosimilar monoclonal antibody (mAb) to be available in the US.

Pfizer will begin shipment of Inflectra (infliximab-dyyb) for injection, a biosimilar of Remicade (infliximab) to wholesalers in the US in late November 2016.

Inflectra will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the US. It is approved for the treatment of

  • Adult patients and pediatric patients (ages six years and older) with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy

  • adult patients with moderate to severely active ulcerative colitis who have had an inadequate response to conventional therapy

  • moderate to severely active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic severe plaque psoriasis.

    • “Biologics have revolutionized the treatment of many life-threatening and chronic diseases. By introducing Inflectra to the US marketplace, Pfizer is helping customers access an additional high quality treatment option that promises greater savings for the healthcare system,” said Diem Nguyen, regional president North America, Pfizer Essential Health Business. “We are proud of our global leadership in biosimilars, and will continue our efforts to advance a sustainable, competitive marketplace for these therapies to deliver a high quality, consistent supply of product and long-term savings and value for patients and physicians.”

    Pfizer holds exclusive commercialization rights to Celltrion’s Inflectra in the US, and has already successfully introduced Infelctra in other markets across the globe.

    Related tags
    Biopharma Market Top Stories

    Related News